PRAME (EP461) Rabbit Monoclonal Primary Antibody
Specialties: Dermatopathology
PRAME (PReferentially-expressed Antigen in MElanoma) is a gene encoded on the 22q11-22 chromosomal sequence and encodes a 509 amino acid residue protein.1 PRAME is a melanoma antigen that is preferentially expressed in tumors and is recognized by cytotoxic T lymphocytes.2,3 PRAME can be used to distinguish between malignant melanoma cells and nevus cells,4 and therefore may be useful for diagnostic purposes to support a suspected case of melanoma. PRAME is considered a cancer-testis antigen (CTA)5 and is not strongly expressed in most other normal tissues. PRAME is positively expressed in about half of uveal melanomas,6 and the majority of mucosal melanomas.7
- Wadelin, Frances et al. "Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia." Molecular cancer vol. 9 226. 27 Aug. 2010, doi:10.1186/1476-4598-9-226
- Lezcano, Cecilia et al. "PRAME Expression in Melanocytic Tumors." The American journal of surgical pathology vol. 42,11 (2018): 1456-1465. doi:10.1097/PAS.0000000000001134
- Ikeda, H et al. "Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor." Immunity vol. 6,2 (1997): 199-208. doi:10.1016/s1074-7613(00)80426-4
- Lezcano, Cecilia et al. "Immunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma." The American journal of surgical pathology vol. 44,4 (2020): 503-508. doi:10.1097/PAS.0000000000001393
- Zhang, Wa et al. "PRAME expression and promoter hypomethylation in epithelial ovarian cancer." Oncotarget vol. 7,29 (2016): 45352-45369. doi:10.18632/oncotarget.9977
- Gezgin, Gulcin et al. "PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma." JAMA ophthalmology vol. 135,6 (2017): 541-549. doi:10.1001/jamaophthalmol.2017.0729
- Toyama, Aimi et al. "Analyses of molecular and histopathologic features and expression of PRAME by immunohistochemistry in mucosal melanomas." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. 32,12 (2019): 1727-1733. doi:10.1038/s41379-019-0335-4
Specifications
- Reactivity: paraffin
- Control: Melanoma (Nuclear)
- Dilution Range: 1:25-1:50 *
Package Inserts
IFU
- IVD Rev. 1.0 (CMC48431010)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 25.0 mL predilute ready-to-use | 484R-10 |
| 0.1 mL concentrate | 484R-14 |
| 0.5 mL concentrate | 484R-15 |
| 1.0 mL concentrate | 484R-16 |
| 1.0 mL predilute ready-to-use | 484R-17 |
| 7.0 mL predilute ready-to-use | 484R-18 |
For research use only (RUO) in Canada
| 25.0 mL predilute ready-to-use (RUO) | 484R-10-RUO |
| 0.1 mL concentrate (RUO) | 484R-14-RUO |
| 1.0 mL concentrate (RUO) | 484R-16-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 484R-17-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 484R-18-RUO |
For in vitro diagnostic (IVD) use in Europe
| 25.0 mL predilute ready-to-use | 484R-10 |
| 0.1 mL concentrate | 484R-14 |
| 0.5 mL concentrate | 484R-15 |
| 1.0 mL concentrate | 484R-16 |
| 1.0 mL predilute ready-to-use | 484R-17 |
| 7.0 mL predilute ready-to-use | 484R-18 |
For research use only (RUO) in Japan
| 25.0 mL predilute ready-to-use (RUO) | 484R-10-RUO |
| 0.1 mL concentrate (RUO) | 484R-14-RUO |
| 1.0 mL concentrate (RUO) | 484R-16-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 484R-17-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 484R-18-RUO |
To request information on this product in additional countries, please click the button below.
